Publicado 09/09/2020 7:01:30 +02:00CET

Final Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances (3

CONTACT: Jim Baxter, Neurology Communications (Global), UCB,T+32.2.473.78.85.01, jim.baxter@ucb.com, Laurent Schots , Media Relations,(Global) UCB, T 32.2.559.92.64, laurent.schots@ucb.com, Investor RelationsAntje Witte, Investor Relations, UCB T+32.2.559.94.14, antje.witte@ucb.com,Isabelle Ghellynck, Investor Relations, UCB, T +32.2.559.95.88,isabelle.ghellynck@ucb.com

Contador